Literature DB >> 14669793

Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Ben Davidson1, Vered Givant-Horwitz, Philip Lazarovici, Björn Risberg, Jahn M Nesland, Claes G Trope, Erik Schaefer, Reuven Reich.   

Abstract

Activation or suppression of intracellular signaling via the mitogen-activated protein kinase (MAPK) family has been linked to expression of matrix metalloproteinases (MMP) in experimental models, but this association has not been demonstrated in clinical material. The objective of this study was to investigate the possible association between expression and activity of MMP, expression of the MMP inducer EMMPRIN, and the expression (level) and phosphorylation status (activity) of the extracellular-regulated kinase (ERK), c-Jun amino-terminal kinase (JNK) and high osmolarity glycerol response kinase (p38) in effusions from patients diagnosed with serous ovarian carcinoma. MAPK level and activity were studied in 55 effusions using immunoblotting. MMP-1, MMP-2, MMP-9 and EMMPRIN expression was studied using immunocytochemistry (ICC) and mRNA in situ hybridization (ISH). The gelatinolytic activity of MMP-2 and MMP-9 was measured by zymography. ERK and phospho-ERK (p-ERK) were detected in 54/55 (98%) and 50/55 (91%) specimens, respectively. JNK and p-JNK were detected in 53/55 (96%) and 38/55 (69%) specimens, respectively. p38 was expressed in 54/55 (98%) specimens, and its phosphorylated form was found in 51/55 (92%). MMP-2 mRNA expression (P = 0.048), protein expression (P = 0.046) and gelatinolytic activity (P = 0.039) correlated with ERK phosphorylative activity. MMP-2 activity also correlated with p38 activity (P = 0.017). MMP-9 protein expression correlated with phosphorylation of p38 (P = 0.046), but enzyme activity showed inverse relationship with both p-ERK (P = 0.05) and p-p38 (P = 0.033) expression. EMMPRIN expression correlated with MMP-1 (P < 0.001), MMP-2 (P = 0.042) and MMP-9 (P = 0.029) expression, as well as with ERK activity (P = 0.001). Our results present the first evidence of a possible link between MAPK signaling and MMP expression and activity in vivo. These data may expand our understanding regarding the mechanisms by which MMP synthesis is regulated in effusions and possibly affect treatment strategies for this form of malignancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669793     DOI: 10.1023/a:1027347932543

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  54 in total

1.  Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.

Authors:  G F Greene; Y Kitadai; C A Pettaway; A C von Eschenbach; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Inhibition of epidermal growth factor-mediated ERK1/2 activation by in situ electroporation of nonpermeant [(alkylamino)methyl]acrylophenone derivatives.

Authors:  H L Brownell; N B Lydon; E Schaefer; T M Roberts; L Raptis
Journal:  DNA Cell Biol       Date:  1998-03       Impact factor: 3.311

Review 3.  MAP kinase pathways activated by stress: the p38 MAPK pathway.

Authors:  T Obata; G E Brown; M B Yaffe
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

Review 4.  Redox-mediated gene therapies for environmental injury: approaches and concepts.

Authors:  J F Engelhardt
Journal:  Antioxid Redox Signal       Date:  1999       Impact factor: 8.401

5.  MMP and TIMP expression pattern in pleural effusions of different origins.

Authors:  O Eickelberg; C O Sommerfeld; C Wyser; M Tamm; F Reichenberger; P G Bardin; M Solèr; M Roth; A P Perruchoud
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

6.  Hyperexpression of mitogen-activated protein kinase in human breast cancer.

Authors:  V S Sivaraman; H Wang; G J Nuovo; C C Malbon
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

7.  Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

Authors:  S M Ellerbroek; J M Halbleib; M Benavidez; J K Warmka; E V Wattenberg; M S Stack; L G Hudson
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38.

Authors:  M Lim; T Martinez; D Jablons; R Cameron; H Guo; B Toole; J D Li; C Basbaum
Journal:  FEBS Lett       Date:  1998-12-11       Impact factor: 4.124

9.  AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients.

Authors:  Ben Davidson; Iris Goldberg; Reuven Reich; Liora Tell; Hiep Phuc Dong; Claes G Trope'; Bjørn Risberg; Juri Kopolovic
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

10.  Acute hypertension activates mitogen-activated protein kinases in arterial wall.

Authors:  Q Xu; Y Liu; M Gorospe; R Udelsman; N J Holbrook
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more
  21 in total

Review 1.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

2.  Up-regulated EMMPRIN/CD147 protein expression might play a role in colorectal carcinogenesis and its subsequent progression without an alteration of its glycosylation and mRNA level.

Authors:  Hua-chuan Zheng; Wei Wang; Xiao-yan Xu; Pu Xia; Miao Yu; Toshiro Sugiyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-01       Impact factor: 4.553

3.  JNK2 Gene Silencing for Elastic Matrix Regenerative Repair.

Authors:  Sarah Carney; Tom Broekelmann; Robert Mecham; Anand Ramamurthi
Journal:  Tissue Eng Part A       Date:  2022-03       Impact factor: 4.080

Review 4.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

5.  Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis.

Authors:  Gopalakrishnan Ramakrishnan; Sundaram Jagan; Sattu Kamaraj; Pandi Anandakumar; Thiruvengadam Devaki
Journal:  Invest New Drugs       Date:  2008-07-30       Impact factor: 3.850

6.  Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma.

Authors:  Che Zhang; Ziliang Tu; Shiming Du; Yong Wang; Qibin Wang
Journal:  Pathol Oncol Res       Date:  2009-07-25       Impact factor: 3.201

Review 7.  CD147 immunoglobulin superfamily receptor function and role in pathology.

Authors:  Kathryn T Iacono; Amy L Brown; Mark I Greene; Sandra J Saouaf
Journal:  Exp Mol Pathol       Date:  2007-09-07       Impact factor: 3.362

8.  CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells.

Authors:  Lu Dai; Maria C Guinea; Mark G Slomiany; Momka Bratoeva; G Daniel Grass; Lauren B Tolliver; Bernard L Maria; Bryan P Toole
Journal:  Am J Pathol       Date:  2012-11-22       Impact factor: 4.307

9.  Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients.

Authors:  Marci E Schaner; Ben Davidson; Martina Skrede; Reuven Reich; Vivi Ann Flørenes; Björn Risberg; Aasmund Berner; Iris Goldberg; Vered Givant-Horwitz; Claes G Tropè; Gunnar B Kristensen; Jahn M Nesland; Anne-Lise Børresen-Dale
Journal:  Mol Cancer       Date:  2005-07-21       Impact factor: 27.401

10.  Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis.

Authors:  H-C Zheng; H Takahashi; Y Murai; Z-G Cui; K Nomoto; S Miwa; K Tsuneyama; Y Takano
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.